Company Overview and News


Add CPH
to your dashboard

Headline News

Cipher Pharmaceuticals Reports Q3 2016 Financial Results

2016-11-11 prnewswire
MISSISSAUGA, ON, Nov. 11, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three months ended September 30, 2016. Unless otherwise noted, all figures are in U.S. currency.

Cipher Pharma Brings Aboard Former Nuvo Pharma Exec as New CFO

2016-09-02 biospace
MISSISSAUGA, ON, Sept. 1, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Stephen L. Lemieux, BA, MMPA, CPA, has been appointed Chief Financial Officer and Secretary of the Company, effective September 12, 2016.  Mr. Lemieux replaces Norman Evans, who, as previously announced, is retiring after almost 10 years as the Chief Financial Officer of Cipher.

Cipher Pharma Shakes Up Board as Four Members Step Down, Effective Immediately

2016-08-09 biospace
MISSISSAUGA, ON, Aug. 9, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher") today announced certain changes to its board of directors (the "Board").

Cipher Pharmaceuticals Out-Licenses Rights to ASF-1096 for Anorectal Disorders

2016-06-20 prnewswire
MISSISSAUGA, ON, June 20, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Edesa Biotech Inc. ("Edesa") has licensed the rights to ASF-1096 (R-salbutamol) for use in anorectal disorders. ASF-1096 is a phase II product candidate that Cipher is investigating as a treatment for selected inflammatory skin disorders. Cipher acquired the global rights to the product in February 2015.

Cipher Pharmaceuticals to Present at Two Upcoming U.S. Investor Conferences

2016-05-31 prnewswire
MISSISSAUGA, ON, May 31, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at two upcoming investor conferences.

Cipher Pharmaceuticals Acquires Worldwide Rights to Dalhousie University's Investigational Tattoo Removal Cream

2016-05-02 prnewswire
MISSISSAUGA, ON, May 2, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has licensed the worldwide rights to develop and commercialize an investigational tattoo removal cream being developed at Dalhousie University in Halifax, Nova Scotia by Alec Falkenham, a PhD student in the Department of Pathology at Dalhousie University. The product candidate, which is applied topically, has shown encouraging results in pre-clinical testing for the removal or reduction of the appearance of tattoos.

Cipher Pharmaceuticals Proposes Adding Rosemary A. Crane and Dr. Renee P. Tannenbaum To Board of Directors

2016-04-07 prnewswire
MISSISSAUGA, ON, April 7, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Rosemary A. (Rose) Crane and Dr. Renee P. Tannenbaum, two pharmaceutical industry leaders, are being proposed for election to Cipher's Board of Directors at the Company's Annual and Special Meeting on May 5, 2016.

Cipher Pharmaceuticals Announces Approvals of Astion Acquired Barrier Creams by Health Canada and the Medicines Evaluation Board

2016-04-06 prnewswire
MISSISSAUGA, ON, April 6, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has received Health Canada approvals for SD Cream and AD Cream (also known as Dermadexin and Pruridexin). Both products were approved in Canada by the Natural and Non-Prescription Health Products Directorate. In addition European approval of Helioclin® Pruritus SD Cream (also known as Pruridexin) was achieved.